KZIA News & Events

Kazia Therapeutics appointed James Levine as CFO, effective June 1. Most recently, Levine served as CFO of Cardiff Oncology, a clinical-stage oncology company developing a PLK1 inhibitor therapy for solid tumors. Prior to Cardiff Oncology, Levine served as CFO of Cidara Therapeutics, an antifungal and antiviral biotech company. He also served as CEO of Verenium Corporation. Earlier in his career, Levine spent 12 years at Goldman Sachs & Co. as a Managing Director advising pharmaceutical and biotech clients.

Kazia Therapeutics appointed Sudha Rao as Chief Scientific Officer, or CSO. Dr. Rao has more than 20 years of experience spanning pharmaceutical R&D, biotechnology, and early clinical development. She currently holds a professorial appointment and leads the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer Medical Research Institute and previously held senior scientific roles at Sanofi/Rhone-Poulenc in the UK. She is the founder and former Chief Scientific Officer of EpiAxis Therapeutics. At Kazia, Dr. Rao will lead all research and development activities.